• Rizwan Ishtiaq Houston Methodist Hospital, Houston, TX
  • Arslan Naeem Maricopa Integrated Health System Phoenix, AZ
  • Iqbal Ratnani Houston Methodist Hospital, Houston, TX


Liposarcoma arising in the thoracic cavity is a rare entity. It is usually found in the retroperitoneal space and the extremities. No case of thoracic liposarcoma in a patient suffering from the end-stage renal disease has been reported in the literature. We herein present the first case of thoracic liposarcoma in a patient suffering from the end-stage renal disease. Metabolic disturbances, increased use of erythropoietin and increased diagnostic workup attributes to greater risk of cancer in patients suffering from renal failure. A chemotherapeutic drug, Trabectedin has been approved for advanced liposarcoma. Prognosis of such tumours depends on the size, location, and their histological subtype.Keyword: End-stage renal disease, Erythropoietin, Liposarcoma, Thoracic cavity, Trabectedin

Author Biographies

Rizwan Ishtiaq, Houston Methodist Hospital, Houston, TX

Department of Critical Care Medicine

Arslan Naeem, Maricopa Integrated Health System Phoenix, AZ

Department of Internal Medicine

Iqbal Ratnani, Houston Methodist Hospital, Houston, TX

Department of Critical Care Medicine


Angarita FA, Cannell AJ, Razak AR, Dickson BC, Blackstein ME. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. BMC Cancer 2016;16(1):30.

Chou CK, Chen ST. Computed tomography identification of an exophytic colonic liposarcoma. Radiol Case Rep 2016;11(3):161–4.

Coindre JM, Pédeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456(2):167–79.

Wyatt SH, Fishman EK, Hruban RH, Siegelman SS. CT of primary colonic lymphoma. Clin Imaging 1994;18(2):131–41.

Ghosh P, Saha K. A rare case of primary anterior chest wall pleomorphic liposarcoma. Saudi J Health Sci 2014;3(2):121–3.

Henze J, Bauer S. Liposarcomas. Hematol Oncol Clin North Am 2013;27(5):939–55.

Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis 2015;65(5):763–72.

Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995;6(1):1–34.

Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296(23):2823–31.

Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells: from clinic to bench - a critical review. Biochim Biophys Acta 2010;1806(1):82–95.

Mentzel T. Biological continuum of benign, atypical, and malignant mesenchymal neoplasms - does it exist? J Pathol 2000;190(5):523–5.

Fujimoto R, Sato M, Miyata R, Minakata K, Omasa M, Kubo T, et al. Successful resection of recurrent mediastinal liposarcoma using preoperative evaluation of organ invasion by four-dimensional computed tomography. Gen Thorac Cardiovasc Surg 2016;64(8):488–91.

Seo JS, Kim YJ, Choi BW, Choe KO. Usefulness of magnetic resonance imaging for evaluation of cardiovascular invasion: evaluation of sliding motion between thoracic mass and adjacent structures on cine MR images. J Magn Reson Imaging 2005;22(2):234–41.

Gemici K, Buldu İ, Acar T, Alptekin H, Kaynar M, Tekinarslan E, et al. Management of patients with retroperitoneal tumors and a review of the literature. World J Surg Oncol 2015;13(1):143.

D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9(8):2157–63.

Thariat J, Etienne-Grimaldi MC, Launay-Vacher V, Soto-Matos A, Fernandez-Teruel C, Ghafari T, et al. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. Cancer Chemother Pharmacol 2011;68(5):1363–7.




Most read articles by the same author(s)